22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
In-Person Event
Dec 12 - 14, 2024
Universal City, California, USA
26.75 AMA PRA Category 1 Credits™ ...OVERVIEW
22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) is organized by The Metabolic Institute of America (TMIOA) and will be held from Dec 12 - 14, 2024 at Hilton Los Angeles/Universal City, Universal City, California, United States of America.
Description:
To make basic and clinical research topics relevant to clinical medicine, following each session there will be a live Q&A and a discussion on implications to clinical practice. To promote more interaction with faculty and provide further insights, each day will end with one hour of the live panel, providing a summary of the day, commentary, and opening for Q&A.
The Congress attracts state-of-the-art abstracts attracting, young up-and-coming researchers as well as recognized leaders from around the globe. The abstracts will be published in Metabolism, a peer-reviewed journal, and will also be available for 90 days on demand.
The congress is featured by many media outlets with proceedings featured in global medical news venues such as Healio, Medscape, Endocrinology & Cardiology Today, Clinical Endocrinology News, Practical Cardiology, HCP Live, and more, while articles are being published in peer-reviewed journals like Journal of Diabetes, Endocrine Practice, Metabolism, Diabetes & Vascular Disease Research, Diabetes, and its complications and others.
Program Objectives:
The program is designed to evaluate both clinical and basic science aspects of diabetes, obesity, CVD, and CKD, focusing on insulin resistance, incretins, the gut, the brain, the kidney, and the heart. The goal is to understand the pathophysiology and develop appropriate comprehensive clinical management plans.
Upon completion of this meeting, participants should be able to:
• Describe the relationship between diabetes, obesity, kidney disease, and heart disease
• Implement best practices for the prevention and management of CKD, HF, and CVD
• Describe the recommended uses of SGLT2 inhibitors for the treatment of HF
• Understand the contemporary role of SGLT2 inhibitors in CKD with and without diabetes
• Describe the benefits of GLP1-RAs in patients with ASCVD or at risk of ASCVD events
• Evaluate the evidence supporting the use of new and emerging therapies to reduce cardiovascular mortality in patients with cardiometabolic disease
• Explain the roles of diabetes and insulin resistance in the development of CKD, HF, and CVD
• Evaluate the impact on the clinical practice of new CVOTs in patients with diabetes and cardiometabolic diseases
• Discuss the effects of insulin resistance on the heart, kidney, and liver
• Design therapeutic regimens for patients with multiple cardiometabolic and renal disorders that capitalize on agents with broad effects across the spectrum of these comorbidities
• Utilize technology to enhance the effectiveness of therapeutics
• Describe the direct and indirect impact of the COVID-19 pandemic on patient health
KEY DATES
12 Dec, 2024
Event Start Date
14 Dec, 2024
Event End Date
ACCREDITATION & CREDITS
AMA PRA Designation Statement:
PESI Inc. has designated this Other (Live and Internet Live ) activity for a maximum of 26.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
MOC Points with ABIM:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Total qualifying MOC points: up to 26.75
International CME:
International Physicians are formally eligible for AMA PRA Category 1 Credit™.
Physician Assistants:
AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME.
Nurses:
For re-certification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.
CA Nurses:
Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 22nd WCIRDC for a total of up to 26.75 contact hours.
Pharmacists:
For re-certification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.
CDE:
The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME providers. Total qualifying continuing education hours: 26.75
Registered Dietitians:
For re-certification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit™.
Satisfactory Completion for Credits:
All attendees must have completed and submitted an online course attendance/evaluation immediately following onsite or virtually live attendance. Each session claimed for credit must be attended in its entirety. Attendees will be able to print a certificate of attendance following the submission of the online evaluation. Physician certificates of credit will be emailed two to three weeks after the CME activity.
Enduring/ On-Demand CME Activity:
This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Designation Statement:
PESI Inc. has designated this Enduring activity for a maximum of 26.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
TARGET AUDIENCE
PhysicianPharmacistPhysician AssistantEndocrinologistsDiabetologistsCliniciansCardiologistsResearchersOncologistsFamily PhysiciansNephrologistsHealthcare ProfessionalsPediatriciansNursesGastroenterologistsOBGYNGeneral InternistsNurse PractitionersOther Health ProfessionalsSPECIALITIES
Cardiovascular DiseaseEndocrinologyNephrologyPatient and Family Centered CareSUGGESTED HOTELS
CONFERENCE VENUE
Hilton Los Angeles/Universal CityRELATED CONFERENCES & LIVE WEBINARS
Quick Links